Automated deformation analysis in the YAC128 Huntington disease mouse model

The YAC128 mouse recapitulates many of the clinical features of Huntington disease (HD), including selective neuropathology with neuronal loss. Here we investigate whether differences in neuroanatomy could be detected using high-resolution magnetic resonance (MR) imaging earlier than the previously defined 9-month age of onset of striatal neuropathology. The striatum is significantly decreased in volume (3.4%, p<0.02) at 8 months of age. A subset of the brains was also analyzed using stereology, and the MR measures were found to be more robust at separating the two groups of mice. Striatal degeneration was found to be asymmetric, with the dorsal and lateral aspects of the striatum being most affected. Non-striatal changes in neuroanatomy were also investigated, revealing regions of expansion as well as atrophy. Our findings suggest that MR imaging can be used to detect and monitor subtle anatomical differences throughout the whole brain and at early time points in the YAC128 mouse-model of HD.

[1]  M. Hayden,et al.  Cognitive Dysfunction Precedes Neuropathology and Motor Abnormalities in the YAC128 Mouse Model of Huntington's Disease , 2005, The Journal of Neuroscience.

[2]  G. Pearlson,et al.  Frontal lobe volume in patients with Huntington's disease , 1998, Neurology.

[3]  M. Hayden,et al.  Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease , 2006, BMC Neuroscience.

[4]  Moo K. Chung,et al.  Deformation-based surface morphometry applied to gray matter deformation , 2003, NeuroImage.

[5]  Arthur W. Toga,et al.  Cerebellar cortical atrophy in experimental autoimmune encephalomyelitis , 2006, NeuroImage.

[6]  D. Louis Collins,et al.  Automatic 3‐D model‐based neuroanatomical segmentation , 1995 .

[7]  M. Hayden,et al.  Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. , 2005, Human molecular genetics.

[8]  N Makris,et al.  Striatal volume loss in HD as measured by MRI and the influence of CAG repeat , 2001, Neurology.

[9]  Alan C. Evans,et al.  A three-dimensional MRI atlas of the mouse brain with estimates of the average and variability. , 2005, Cerebral cortex.

[10]  Claire-Anne Gutekunst,et al.  A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration , 1999, Neuron.

[11]  B R Rosen,et al.  1H NMR spectroscopy studies of Huntington's disease , 1998, Neurology.

[12]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[13]  R. Mark Henkelman,et al.  Sexual dimorphism revealed in the structure of the mouse brain using three-dimensional magnetic resonance imaging , 2007, NeuroImage.

[14]  Jonathon Bishop,et al.  Magnetic resonance imaging for detection and analysis of mouse phenotypes , 2005, NMR in biomedicine.

[15]  Alan C. Evans,et al.  A Unified Statistical Approach to Deformation-Based Morphometry , 2001, NeuroImage.

[16]  E. Simpson,et al.  Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. , 2003, Human molecular genetics.

[17]  J. Ashburner,et al.  Progression of structural neuropathology in preclinical Huntington’s disease: a tensor based morphometry study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[18]  Blair R. Leavitt,et al.  Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease , 2005, Experimental Neurology.

[19]  Elizabeth H. Aylward,et al.  Change in MRI striatal volumes as a biomarker in preclinical Huntington's disease , 2007, Brain Research Bulletin.

[20]  Michael Dragunow,et al.  Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[22]  Wilhelm Gaus,et al.  Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis , 2004, Neurology.

[23]  Natasa Kovacevic,et al.  Neuroanatomical differences between mouse strains as shown by high-resolution 3D MRI , 2006, NeuroImage.

[24]  J. Brandt,et al.  Onset and rate of striatal atrophy in preclinical Huntington disease , 2004, Neurology.

[25]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[26]  Jane S. Paulsen,et al.  Brain Structure in Preclinical Huntington’s Disease , 2006, Biological Psychiatry.

[27]  Thomas E. Nichols,et al.  Thresholding of Statistical Maps in Functional Neuroimaging Using the False Discovery Rate , 2002, NeuroImage.

[28]  R. Faull,et al.  The distribution of progenitor cells in the subependymal layer of the lateral ventricle in the normal and Huntington’s disease human brain , 2005, Neuroscience.

[29]  J. Michael Tyszka,et al.  Statistical diffusion tensor histology reveals regional dysmyelination effects in the shiverer mouse mutant , 2006, NeuroImage.

[30]  J. Roder,et al.  In Vivo Magnetic Resonance Imaging and Semiautomated Image Analysis Extend the Brain Phenotype for cdf/cdf Mice , 2006, The Journal of Neuroscience.

[31]  M. Hayden,et al.  Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease , 2005, Journal of neurochemistry.

[32]  D. Collins,et al.  Automatic 3D Intersubject Registration of MR Volumetric Data in Standardized Talairach Space , 1994, Journal of computer assisted tomography.

[33]  Y. W. Liu,et al.  Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease , 2004, Neuroscience.